top
Search terms
Results 1 - 10 of 31 - ordered by :
Pages: 1 2 3 4
Ejhf

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF) Original ArticleAuthors Jane A. ...

European Journal of Heart Failure, Cannon, Jane A., Collier, Timothy J., Shen, Li, Swedberg, Karl, Krum, Henry, Van Veldhuisen, Dirk J., Vincent, John, Pocock, Stuart J., Pitt, Bertram, Zannad, ...

Date : 01/07/2015 Item size : 180262 bytes
Ejhf

ComorbidityAuthors Preiss David, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UKSearch for more papers by this author van Veldhuisen Dirk J., Department of ...

European Journal of Heart Failure, Preiss, David, Veldhuisen, Dirk J., Sattar, Naveed, Krum, Henry, Swedberg, Karl, Shi, Harry, Vincent, John, Pocock, Stuart J., Pitt, Bertram, Zannad, Faiez, ...

Date : 01/08/2012 Item size : 171966 bytes
Ejhf

Introduction Composite outcomes are frequently adopted as primary endpoints in clinical trials as they take account of both the fatal and non-fatal consequences of the disease under study, thereby ...

European Journal of Heart Failure, Rogers, Jennifer K., Pocock, Stuart J., McMurray, John J.V., Granger, Christopher B., Michelson, Eric L., Östergren, Jan, Pfeffer, Marc A., Solomon, Scott D., ...

Date : 01/01/2014 Item size : 166873 bytes
Ejhf

Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40] European ...

European Journal of Heart Failure, Rogers, Jennifer K., Pocock, Stuart J., McMurray, John J.V., Granger, Christopher B., Michelson, Eric L., Östergren, Jan, Pfeffer, Marc A., Solomon, Scott D., ...

Date : 01/05/2014 Item size : 45152 bytes
Ejhf

Tel: +44 151 228 1616, Email: nathawkins@hotmail.com Search for more papers by this author Wang Duolao, Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UKSearch for ...

European Journal of Heart Failure, Hawkins, Nathaniel M., Wang, Duolao, Petrie, Mark C., Pfeffer, Marc A., Swedberg, Karl, Granger, Christopher B., Yusuf, Salim, Solomon, Scott D., Östergren, Jan, ...

Date : 01/06/2010 Item size : 208846 bytes
Ejhf

The purpose of this subgroup analysis was to explore the interaction between baseline aspirin treatment and the effect of eplerenone on the primary efficacy outcomes (composite of hospitalization for ...

European Journal of Heart Failure, Chin, Ken Lee, Collier, Timothy J., Pitt, Bertram, McMurray, John J.V., Swedberg, Karl, van Veldhuisen, Dirk J., Pocock, Stuart J., Vincent, John, Turgonyi, Eva, ...

Date : 01/09/2016 Item size : 53437 bytes
Ejhf

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document In ASCEND-HF, specific clinical variables including older age, ...

European Journal of Heart Failure, Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael ...

Date : 01/10/2013 Item size : 366395 bytes
Ehjournal

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme Abstract Aims The ...

European Heart Journal, Pocock, Stuart J., McMurray, John J.V., Dobson, Joanna, Yusuf, Salim, Granger, Christopher B., Michelson, Eric L., Östergren, Jan, Pfeffer, Marc A., Solomon, Scott D., ...

Date : 01/11/2008
Ehjournal

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF ...

European Heart Journal, Collier, Timothy J., Pocock, Stuart J., McMurray, John J.V., Zannad, Faiez, Krum, Henry, van Veldhuisen, Dirk J., Swedberg, Karl, Shi, Harry, Vincent, John, Pitt, Bertram

Date : 21/09/2013 Item size : 204282 bytes
Ehjournal

Bleeding risks are typically dose related, making selection of the optimal dose (or preferably, doses) to advance from phase II to III testing a critical step in drug development.1 Efficacy is ...

European Heart Journal, Verheugt, Freek W.A., Clemmensen, Peter, Mehran, Roxana, Agewall, Stefan, Pocock, Stuart J., Goldstein, Sidney, Torp-Pedersen, Christian, Simoons, Maarten L., Borer, Jeffrey ...

Date : 07/06/2013